4th November 2014
Blueberry announces that it has started collaborating with The University of Sheffield and Sheffield Hallam University to explore development of new anti-fungal drugs and treatments. This collaborative project brings together leading academics at both of Sheffield’s world-class universities with Blueberry’s drug discovery and development expertise and will explore the development of new drugs and treatments for a wide range of fungal infections.
You can read the full press release here
22nd May 2014
Chief Scientific Officer David Cook publishes a major paper in Nature Reviews Drug Discovery
David’s paper written with colleagues from AstraZeneca is entitled “Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework” and is a comprehensive analysis of AstraZeneca’s portfolio between 2005-2010. The paper examines in detail the root-causes for drug project failure and identifies several features (“The 5Rs”) which describe successful R&D programmes.
David said “This paper presents the outcome of a major portfolio review performed within AstraZeneca and identifies lessons and principles that are applicable to all drug discovery and development projects. By adopting these principles we can ensure that we maximize the likely success of our projects by having a clear understanding of patient needs and how new drugs will meet these needs. These principles also help us focus programmes on efficiently answering the key questions that must be addressed during R&D if we are to bring new treatments to patients and the market."
22nd May 2014
Blueberry begins a collaboration with the University of Manchester exploring the mode of action and therapeutic potential of novel antiflammatory agents.
Blueberry Therapeutics (Blueberry) today announced that it had started a collaboration with Professor Ian Kimber and Dr. Rebecca Dearman at the University of Manchester to research the potential of novel antiflammatory agents. This project will explore the feasibility of these approaches for the treatment of a range of skin disorders including atopic dermatitis, psoriasis and acne. The collaboration is supported through a BBSRC Sparking Impact award made to the University of Manchester.
You can read the full press release here
11th March 2014
Blueberry partnered with the Health KTN, BioHub and Bionow to host a conference on Innovation and Challenges for Next Generation Anti-Infective Therapeutics.
Blueberry Therapeutics were delighted to be a partner at the recent conference on “Innovations and Challenges for Next Generation Anti-Infective Therapeutics”. The event was organized by the Health Knowledge Transfer Network and was held at The Alderley Park Conference centre. The event brought together an exciting mix of companies and groups all exploring novel approaches to developing anti-infective treatments. Chief Scientific Officer David Cook presented Blueberry’s long-term strategic vision as well as some of their latest results.
You can see David’s presentation here
CSO David Cook presents at the Innovations and Challenges for Next Generation Anti-Infective Therapeutics conference
17th January 2013
Blueberry starts collaborating with the University of Manchester and University of Liverpool to explore development of novel broad spectrum antibiotics
Blueberry Therapeutics (Blueberry) today announced that it has started collaborating with the University of Manchester and University of Liverpool to explore development of a novel broad-spectrum antibiotic. This collaborative project brings together leading academics at the Universities of Manchester and Liverpool with Blueberry’s drug discovery and development expertise and will explore the feasibility of a new approach for the treatment of Gram-negative bacterial infection. The collaboration is supported through a BBSRC Sparking Impact award made to the University of Manchester.
You can read the full press release here.
News Archive
17th October 2013: Blueberry signs therapeutic licensing agreement for the use of Affimers. Blueberry Therapeutics has signed a licensing agreement with Avacta Group plc for the use of Affimers in the development of new therapies for the treatment of multi-drug resistant bacterial infection. You can read the Avacta press release here.
14th October 2013: Dr David Cook joins the Blueberry Management Team as Chief Scientific Officer
6th September 2013: Blueberry Therapeutics wins a prestigious Technology Strategy Board (TSB) Catalyst Award to support the development of new therapies for the treatment of multi-drug resistant bacterial infection.
3rd September 2013: Dr Wal Ward joins the Blueberry Scientific Advisory Board.
15th June 2013: Dr Alex O'Neill an expert in multidrug resistance and the development of novel antibacterial agents joins the Blueberry Scientific advisory board
7th May 2013: Blueberry moves into new laboratories at the BioHub at Alderley Park, Cheshire. Click here to read more
7th February 2013: The Blueberry Board attended the Scottish Enterprise Life Science Annual Awards Dinner as guests of Innova Partnerships and DC consulting. The team were impressed by the vibrant, energised life sciences community in Scotland and their big ambitions.
6th November 2012: Blueberry signs an exclusive licensing agreement with a nanoparticle delivery system partner.
1st November 2012: Tony Sedgwick joins Blueberry advisor to the Board
25th October 2012: Dr Jin Li and Dr Liam Good, join the Blueberry Scientific Advisory Board bring with them a wealth of scientific and drug discovery expertise.
13th October 2012: Prof. Tim Walsh, world-renowned expert in mechanisms of multi-drug resistance, joins the Blueberry Scientific Advisory Board
8th October 2012: Drug delivery and formulation expert Dr Maria Marlow joins the Blueberry Scientific Advisory Board
27th September 2012: Dr John Ridden presented at the EU-China Business and Cooperation summit in Chengdu
4th Sept 2012: Dr Dave Cook joins Blueberry Scientific Advisory Board
30th May 2012: Dr John Ridden & Dr Mike Davies present at the Babraham Investors Forum
2nd April 2012: AstraZeneca assign 5 compound assets to Blueberry Therapeutics Ltdhttp://www.avacta.com/